louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02832310: The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems
Official title: The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asymptomatic Diseases
Keywords: valsalva
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: peroperative patients, healhty volunteers

Brief summary: The aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver.

Detailed description: The aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver. A total of 70 patients in preoperative period will enroll in this study. After a deep inspiration, patients will asked to exhale to a valf system with a flow pressure of 20-40 mmHg and duration of 15 seconds. During valsalva maneuver, the diameter and flow rates of carotis interna, brachial artery and radial artery will measure using ultrasound. All data will be recorded.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists score of I, II, III

Exclusion Criteria:

* Morbid obesity (body mass index over 40)
* Not to participate in the study
* Psychiatric diseases
* Peripheral vascular diseases

Primary outcomes:
measure: arterial flow rate
timeFrame: 1 year
Secondary outcomes:
measure: arterial diameter
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00679510: Rosuvastatin in Rheumatoid Arthritis (RORA)
Official title: Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis
Rosuvastatin
Cardiovascular
Intima media thickness
Lead sponsor: University of Dundee
Sponsor class: OTHER
First posted: 2008-05-19
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. The investigator's study is aimed at looking at the effects of proven cholesterol lowering treatment drug called rosuvastatin in rheumatoid arthritis patients on few cardiovascular markers. Endothelial behaviour improved on treatment.


Eligibility criteria: Inclusion Criteria:

* Patients will be selected from a high risk population of hospital clinic attendees, defined as RA greater than 5 years' disease duration, and all will be RA latex seropositive or IgM RF ELISA \>14iu/ml. The subjects will be of either sex and \>40 years of age.
* Patients should have both tender and swollen joint counts \>4 each and either a CRP \>10mg/l, ESR \>25mm/h or PV \>1.78.
* Patients on cyclosporine or other medications known to be contraindicated with this form of drug will not be enrolled.

Exclusion Criteria:

* The patient's hospital and general practice records will be scrutinised for evidence of symptomatic vascular disease.
* Any patient not free from vascular disease symptoms will be excluded.
* In addition to evidence of symptomatic vascular disease (either previous or current), the exclusion criteria consist also of those already taking lipid-lowering therapy or those with contraindications to these therapies.
* Also excluded will be subjects with a total cholesterol level of \>7.5mmol/L as it might be argued that such patients merit primary prevention on the basis of dyslipidemia alone.

Primary outcomes:
measure: measurement of intima media thickness
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dundee
country: United Kingdom
facility: University of Dundee
Study officials:
affiliation: University of Dundee
name: Jill Belch, MD FRCP
role: STUDY_CHAIR
References:
citation: Kumar P, Kennedy G, Khan F, Pullar T, Belch JJ. Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scott Med J. 2012 May;57(2):80-3. doi: 10.1258/smj.2012.012004.
Clinical trial NCT06244810: Comparison of Two Types of Lingual Fixed Retainer Fabricated
Official title: Comparison of Two Types of Lingual Fixed Retainer (Metal and Fiber)Fabricated by Using (CAD\CAM)Technique
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malocclusion, Angle's Class
Lead sponsor: Hama University
Sponsor class: OTHER
First posted: 2024-02-06
Enrollment: 42
Sex: ALL
Minimum age (years): 14
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study includes patients who have had previous orthodontic treatments (without tooth extraction) and who have good alignment of their lower incisors. Investigators will compare two types of lingual retainers made with CAD-CAM

Detailed description: This study includes patients who have had previous orthodontic treatments (without tooth extraction) and who have good alignment of their lower incisors. Investigator will compare two types of lingual retainers made with CAD-CAM by comparing them with the traditional lingual retainers according to the following groups:

1. Patients will be apply to them a lingual retainer made of fibers manufactured using CAD-CAM technology
2. Patients will be apply to them a lingual retainer made of metal made using CAD-CAM technology
3. Patients will be apply to them a conventional lingual retainer made of braided stainless steel wire (control group)

Eligibility criteria: Inclusion Criteria:

* Patients with mixed dentition at age 14-24 years. They have a good alignment of the lower incisors.- Have good oral and periodontal health.-

Exclusion Criteria:

Patients who have a deep bite Patients who have previously used retainer Patients with poor oral care

Primary outcomes:
measure: Bacterial plaque indicator
timeFrame: 6 months
measure: Patient Acceptance Assessment:
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Damascus
country: Syrian Arab Republic
facility: FADI Alhaji JNAID
state: None Selected
Study officials:
affiliation: Hama University-Syrian Arab Republic
name: Manar A Warrar, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Professor of Orthodontics, University of Hama Dental School, Hama, Syria.
name: Rabab Alsabbagh, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT00129610: Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia
Official title: A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Panic Disorder
Agoraphobia
Keywords: Agoraphobia
panic disorder
Virtual Reality Therapy
Cognitive Behavior Therapy
cognition
spatial cognition
PANIC DISORDER WITH AGORAPHOBIA
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2005-08-12
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: ECT

Brief summary: The study aims at comparing virtual reality therapy (VRT) with a usual cognitive behavior therapy (CBT) program for agoraphobia. A waiting list represents the control condition. The investigators' purpose is to test a pure VRT compared with a pure CBT, as previous works suggest that the combination of the two methods are clinically effective. Patients receive a two-page information leaflet about the trial and sign an informed consent. After the first evaluation, they are randomized, in three centers (Lyon, Paris, Luxemburg), either to VRT (12 sessions) or CBT (12 sessions), or a waiting-list control condition for three months. After three months the waiting list is randomized to VRT or CBT. The follow-up is one year from entry into the active part of the trial.


Eligibility criteria: Inclusion Criteria:

* The study includes 90 patients, aged from 18 to 60, with DSM-4 panic disorder with agoraphobia.
* Patients should not be clinically depressed and present a Hamilton Scale of Depression score of less than 18.

Exclusion Criteria:

* Patients with active medication (antidepressants, neuroleptics, mood stabilizers, benzodiazepines, Kava Kava, or hypericum) or street drugs. Minor herbal medicine is tolerated.

Primary outcomes:
measure: The response criterion is a decrease of 50% of the agoraphobia subscore on the Fear Questionnaire
Secondary outcomes:
measure: Pre-test, post-test, 6 months and one year
measure: Panic Disorder Severity Scale
measure: Agoraphobic cognitions
measure: Panic, phobia, generalized anxiety
measure: Trait State Anxiety Inventory (STAI)
measure: Hamilton Anxiety Scale
measure: Dissociative experiences
measure: Beck Depression Inventory
measure: Quality of Life, handicap
measure: Spatial cognition: Rey's Figure and Rod and Frame test
measure: Therapeutic expectations (pre-test)
measure: Therapeutic relationship (post-test)
Other outcomes:
Locations:
city: Bron
country: France
facility: Hôpital Pierre Wertheimer
Study officials:
affiliation: Hospices Civils de Lyon
name: Jean COTTRAUX, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06043310: Estrogen and Microvascular Function
Official title: Effects of Continuous Estrogen on Human in Vivo Microvascular Function
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Estrogen
Cardiovascular Diseases
Microvasculature
Oral Contraceptive Use
Keywords: Female
oral contraceptive
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 45
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community sample

Brief summary: The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults.

Participants will:

* give one blood draw of 5 mL
* have one Dexa Scan taken to measure adipose and muscle mass
* have a camera placed under the tongue to take pictures of blood vessels
* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen to those who do not.


Eligibility criteria: Inclusion Criteria:

Estrogen/Progestin Group

* Adults aged 18-40 years
* Females with estrogen/progestin treatment for a minimum of 1 year.
* Blood pressure \<140/ \< 90 mmHg
* No more than 1 cardiovascular risk factor Control Groups
* Adults aged 18-40 years
* Female with no estrogen/progestin treatment for minimum of 5 years.
* Female undergoing progestin only treatment for a minimum of 1 year.
* Blood pressure \<140/ \< 90 mmHg
* No more than 1 cardiovascular risk factor

Exclusion Criteria:

* Medications that could alter cardiovascular control
* Rash, skin disease, or pigmentation disorders on both forearms
* Anemia
* Kidney Disease
* Known skin allergies
* Smoking or tobacco use within last 6 months
* Coronary Artery Disease

  -1 cardiovascular risk factor Hypertension Diabetes Hypercholesterolemia Hyperlipidemia
* Bleeding disorders
* Use of anti-coagulants
* Allergies to study drugs
* Use of topical/non-topical steroids in last 6 months
* Internal mouth sores
* Forearms covered with tattoos
* Pregnancy

Primary outcomes:
measure: Change in blood vessel dilation
timeFrame: 2 hours
measure: Change in Perfused Vessel Density
timeFrame: 0.5 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Wauwatosa
country: United States
facility: Froedtert Hospital
state: Wisconsin
Study officials:
References:
Clinical trial NCT01306110: Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
Official title: Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Keywords: Liver fibrosis
diabetes
Fibroscan
Fibrotest
noninvasive fibrosis biomarkers
Lead sponsor: Association HGE CHU Bordeaux Sud
Sponsor class: OTHER
First posted: 2011-03-01
Enrollment: 277
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diabetes

Brief summary: The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.

Detailed description: Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects
* More than 18 years of age
* Patients with Diabetes
* Written informed consent

Exclusion Criteria:

* Patients refusing to participate to the study and to provide written informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pessac
country: France
facility: Service Hepato-Gastroentérologie Hopital Haut-Leveque
Study officials:
affiliation: University Hospital, Bordeaux
name: Victor De Ledinghen, MD PhD
role: STUDY_DIRECTOR
affiliation: University Hospital, Bordeaux
name: Juliette Foucher, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Bordeaux
name: Julien Vergniol, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Bordeaux
name: Vincent Rigalleau, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06428110: A Prospective Cohort Study on Warfarin Personalized Medication
Official title: Personalized Medication Research of Warfarin Based on Vascular Aging Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Warfarin Sodium Causing Adverse Effects in Therapeutic Use
Lead sponsor: Shanghai 5th People's Hospital
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 272
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients taking warfarin

Brief summary: Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.


Eligibility criteria: Inclusion Criteria:

* Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.

  * Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.

    * Signing an informed consent form before blood sample collection.

Exclusion Criteria:

* Patients who are allergic to warfarin or lactose.

  * Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.

    * Patients with bleeding tendencies, blood disorders with platelet counts \> 400 × 10\^9 /L or \< 100 × 10\^9 /L, hemoglobin \> 169 or \< 100 g/L.

      * History of peptic ulcer disease.

        * Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.

          * Neurological disorders such as epilepsy.

Primary outcomes:
measure: Numbers of patients with bleeding events
timeFrame: 1 year during the follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: The Fifth People's Hospital of Shanghai
state: Shanghai
Study officials:
affiliation: The Fifth People's Hospital of Shanghai
name: Guangchun Sun
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05932810: Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial Needs of Individuals Living With Cancer
Official title: Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial Needs of Individuals Living With Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Depressive Symptoms
Cancer
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2023-07-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by the investigators to assist with the treatment of depressed mood.

Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not.

All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as the participant's experiences using Moodivate and participating in this trial. Participation in this study will take about 4 weeks, beginning today.

Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include the participant contacting their primary care provider or their oncology care team to discuss other available treatments for depressed mood.


Eligibility criteria: Inclusion Criteria:

1. elevated depressive symptoms, defined as a score of ≥ 10 on the PHQ-936
2. ILLIC (as determined during manual chart review)
3. age 18+
4. currently own an iOS- or Android-compatible smartphone
5. report willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item)
6. have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments)
7. English fluency

Exclusion Criteria:

1. Severe cognitive impairment that precludes completion of informed consent
2. current suicidal ideation on the PHQ-9 at screening or final study eligibility, defined as a response ≥1 (several days) on item nine

Primary outcomes:
measure: Accrual
timeFrame: Study duration (6-7 months or until recruitment is reached)
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: Jennifer Dahne, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01070810: Thiamine as a Metabolic Resuscitator in Septic Shock
Official title: Thiamine as a Metabolic Resuscitator in Septic Shock
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Septic Shock
Keywords: Septic Shock
Sepsis
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Center for Complementary and Integrative Health (NCCIH)
First posted: 2010-02-18
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The major goal of this project is to determine whether the use of thiamine in patients with septic shock will result in attenuation of lactic acidosis and a more rapid reversal of shock.


Eligibility criteria: Inclusion Criteria:

* Greater than 18 years old
* Suspected or confirmed source of infection
* Hypotension (systolic pressure \<90 mmHg) after a minimum 2 liter fluid bolus followed by vasopressor-dependence.
* Lactic Acidosis \> 3 mmol/dl

Exclusion Criteria:

* Competing cause of lactic acidosis including: seizures within 3 hours of enrollment, use of linazolid metformin or anti-retrovirals at the time of enrollment, carbon monoxide or cyanide poisoning, highly suspected or known ischemic bowel, and known mitochondrial disorders
* Liver dysfunction specifically defined as AST or ALT elevation greater than 240
* Current Thiamine supplements or usage
* Competing indication for thiamine administration
* Cardiac Arrest
* DNR/DNI or comfort care status (DNR status in an intubated patient receiving full care is eligible)

Primary outcomes:
measure: Lactate Level 24 Hours After the First Study Medication Dose
timeFrame: 24 hours
Secondary outcomes:
measure: Number of Participants With Shock Reversal
timeFrame: Hospital stay, average 2 weeks
measure: APACHE II Score at 24 Hours
timeFrame: 24 hours
Other outcomes:
measure: Lactate Level at 24 Hours in Patients With Baseline Thiamine Deficiency
timeFrame: 24 hours
measure: Number of Participants Dying Before Hospital Discharge in Patients With Baseline Thiamine Deficiency
timeFrame: Hospital stay, average 2 weeks
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
affiliation: Beth Israel Deaconess Medical Center
name: Michael W Donnino, MD
role: PRINCIPAL_INVESTIGATOR
References: